Thousand Oaks-based Amgen Inc.’s stock experienced a significant rise on Monday following news that Goldman Sachs initiated coverage of the biotech giant with a buy recommendation.
Amgen Inc. announced the start of a collaboration with Neumora Therapeutics, a clinical-stage biopharma company specializing in brain disease medicines.
Amgen Inc. on Wednesday announced it will sponsor BioLabs LA at the Lundquist Institute, a biotech co-working space in Torrance, via a three-year Golden Ticket program.
Through the program, Thousand Oaks-based Amgen will launch one Golden Ticket award each year of its sponsorship, providing the winning startup with one year of lab space at BioLabs LA and access to lab infrastructure, programming and business development mentorship.
The sponsorship’s monetary value was not disclosed.
“Recognizing the growing biotech ecosystem in Southern California, Amgen’s sponsorship of the Golden Ticket with BioLabs aims to further foster early-stage life science companies right in the backyard of Amgen’s headquarters,” Dr. Philip Tagari, vice president of therapeutic discovery at Amgen, said in a statement.